Peptide
ACE-031
SaveA soluble activin receptor type IIB (ActRIIB-Fc) that acts as a myostatin/activin trap, investigated for muscle-wasting conditions.
Quick verdict
Phase II trial in Duchenne muscular dystrophy was halted due to vascular safety signals. Clinical development has been discontinued.
Evidence score
A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.
What the research shows
One completed phase II trial showed lean mass gains but was stopped for epistaxis and telangiectasia. No further development announced.
Benefits
- Increased lean body mass in early trial data
- Theoretical utility in severe muscle-wasting disorders
Dosage notes
No validated dosing for general use. Trial doses were 0.5–3 mg/kg IV every two weeks.
Side effects
- Epistaxis
- Gingival bleeding
- Skin telangiectasia
- Dilated superficial blood vessels
Who should be cautious
Development halted due to safety concerns. No approved use in any jurisdiction.
What this page cannot tell you
Only short-term human data exists from a discontinued trial. Long-term safety is unknown.
Leaderboard scores
- Muscle35
- Recovery20
Write a review
Sign in to write a review.